NCT04377048View on ClinicalTrials.gov

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

July 1, 2022

Study Completion Date

December 31, 2022

Conditions
Stage IV Pancreatic Cancer
Interventions
DRUG

Nivolumab

"as described in NGS Arm"

DRUG

Gemcitabine

"as described in NGS Arm"

DRUG

Tegafur-Gimeracil-Oteracil

"as described in NGS Arm"

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

collaborator

ACT Genomics

INDUSTRY

collaborator

TTY Biopharm

INDUSTRY

lead

National Taiwan University Hospital

OTHER

NCT04377048 - Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter